Insider Selling: Liquidia (NASDAQ:LQDA) Insider Sells $31,356.48 in Stock

Liquidia Corporation (NASDAQ:LQDA) insider Sanjeev Khindri sold 1,101 shares of the company’s stock in a transaction that occurred on Monday, October 12th. The stock was sold at an average price of $28.48, for a total transaction of $31,356.48. Following the completion of the transaction, the insider owned 64,846 shares in the company, valued at approximately $1,846,814.08. This represents a 1.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Liquidia Stock Performance

NASDAQ:LQDA opened at $34.78 on Friday. Liquidia Corporation has a fifty-two week low of $21.94 and a fifty-two week high of $93.61. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.12 and a current ratio of 2.31. The company has a 50 day moving average price of $61.21 and a 200 day moving average price of $61.73. The stock has a market capitalization of $3.11 billion, a P/E ratio of 24.77 and a beta of 0.61.

Liquidia (NASDAQ:LQDA) last announced its earnings results on Wednesday, August 12th. The company reported $0.74 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.02). The firm had revenue of $171.68 million during the quarter, compared to analysts’ expectations of $168.48 million. Liquidia had a net margin of 30.74% and a return on equity of 149.65%. The firm’s revenue for the quarter was up 1842.1% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.49) EPS. Equities research analysts forecast that Liquidia Corporation will post 2.05 EPS for the current year.

Institutional Investors Weigh In On Liquidia

A number of hedge funds have recently added to or reduced their stakes in LQDA. Bank of America Corp DE boosted its position in Liquidia by 18.7% in the 1st quarter. Bank of America Corp DE now owns 2,287,792 shares of the company’s stock valued at $86,341,000 after buying an additional 360,372 shares during the period. Bank of New York Mellon Corp acquired a new position in shares of Liquidia in the second quarter worth $29,694,000. Eversept Partners LP increased its position in shares of Liquidia by 33.0% during the first quarter. Eversept Partners LP now owns 677,392 shares of the company’s stock worth $25,565,000 after acquiring an additional 167,949 shares during the period. Seven Fleet Capital Management LP increased its position in shares of Liquidia by 25.2% during the second quarter. Seven Fleet Capital Management LP now owns 256,603 shares of the company’s stock worth $20,459,000 after acquiring an additional 51,727 shares during the period. Finally, Pale Fire Capital SE increased its position in shares of Liquidia by 2.4% during the first quarter. Pale Fire Capital SE now owns 388,377 shares of the company’s stock worth $14,657,000 after acquiring an additional 8,985 shares during the period. 64.54% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Liquidia

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Liquidia settled all six patent and antitrust disputes with United Therapeutics for a net $380.7 million, allowing continued commercialization of YUTREPIA for pulmonary arterial hypertension. Ending the litigation removes significant legal uncertainty and avoids a potentially market-disrupting appeal. Liquidia shares surge as settlement ends United Therapeutics litigation
• Positive Sentiment: Analyst sentiment improved after the settlement. LifeSci Capital upgraded LQDA to “outperform” with a $59 price target, while HC Wainwright raised its target to $65 and initiated or reiterated a “buy” rating. BTIG also upgraded the stock to “buy” with a $70 target. LifeSci Capital upgrades Liquidia
• Positive Sentiment: Preliminary third-quarter YUTREPIA net product sales were reported at $222.7 million. Management expects existing cash and ongoing sales to fund the settlement and planned clinical programs without requiring additional financing, supporting the investment case if commercial momentum continues.
• Positive Sentiment: Trading activity reflected renewed speculative interest, with call-option volume more than doubling its typical level. This suggests some traders are positioning for additional gains following the legal resolution.
• Neutral Sentiment: Multiple executives and insiders, including the CEO and CFO, sold shares at $28.48 under pre-arranged Rule 10b5-1 plans to cover tax obligations on vested equity awards. Because the transactions were planned and sellers retained substantial holdings, they are a limited standalone signal of sentiment. Liquidia insider sale filing
• Negative Sentiment: The $380.7 million settlement will require $175 million within 30 business days, $145.4 million in 2027 installments and $60.3 million tied to antitrust litigation. These payments could materially reduce Liquidia’s cash cushion and constrain future investment.
• Negative Sentiment: Liquidia agreed not to appeal the infringement ruling and will remove the PH-ILD indication from YUTREPIA’s label, narrowing the drug’s addressable market. Needham lowered its price target to $58, despite maintaining a “buy” rating, highlighting ongoing execution and valuation risks.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on LQDA. Citigroup reaffirmed a “neutral” rating on shares of Liquidia in a research note on Thursday, October 1st. Piper Sandler set a $129.00 target price on Liquidia in a research note on Friday, July 24th. Wall Street Zen lowered Liquidia from a “buy” rating to a “hold” rating in a research note on Saturday, October 3rd. Bank of America raised their target price on Liquidia from $79.00 to $92.00 and gave the company a “neutral” rating in a report on Thursday, August 13th. Finally, Weiss Ratings raised Liquidia from a “sell (d-)” rating to a “hold (c)” rating in a research report on Tuesday, September 22nd. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, four have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, Liquidia currently has a consensus rating of “Hold” and an average price target of $72.85.

Liquidia Company Profile

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with serious cardiopulmonary diseases and other rare conditions. The company uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition, with the goal of improving the delivery and performance of medicines.

Liquidia’s lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder inhaler designed for the treatment of pulmonary arterial hypertension (PAH).